ArticleJournal of neuroinflammation2012
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Article in Journal of neuroinflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- Single-Cell RNA sequencing identifies NAMPT as a potential therapeutic target in autoimmune uveitis.Journal of advanced research · 2026Article
- hUC-MSCs via β-NGF Alleviate Cognitive Impairment After Tibial Fracture Surgery by Regulating the STMN2/NMNAT2-SARM1-NF-κB Signaling Pathway.CNS neuroscience & therapeutics · 2026Article
- Deficiency of SARM1 attenuates neuronal injury and improves neurological performance in a photothrombotic stroke model.Molecular brain · 2025Article
- Tumor immune microenvironment of colorectal cancer identifies novel prognostic signature and potential therapeutic drugs.Cancer biomarkers : section A of Disease markers · 2024Article
- Hypothalamic astrocyte NADNature communications · 2024Article
- Nicotinamide Adenine Dinucleotide (NADAntioxidants & redox signaling · 2023Review
- The molecular mechanism of cardiac injury in SARS-CoV-2 infection: Focus on mitochondrial dysfunction.Journal of infection and public health · 2023Article
- Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons.Neurobiology of disease · 2022Article
- Alpha-synucleinopathy reduces NMNAT3 protein levels and neurite formation that can be rescued by targeting the NAD+ pathway.Human molecular genetics · 2022Article
- Review
- Berberine Attenuates Neonatal Sepsis in Mice By Inhibiting FOXA1 and NF-κB Signal Transduction Via the Induction of MiR-132-3p.Inflammation · 2021Article
- Adipokines as Immune Cell Modulators in Multiple Sclerosis.International journal of molecular sciences · 2021Review
- Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Lipopolysaccharide-Induced Microglial Neuroinflammation: Attenuation by FK866.Neurochemical research · 2021Article
- SARM1 promotes neuroinflammation and inhibits neural regeneration after spinal cord injury through NF-κB signaling.Theranostics · 2021Article
- Catalytic, Transition-Metal-Free Semireduction of Propiolamide Derivatives: Scope and Mechanistic Investigation.Organic letters · 2020Article
- Neuroprotective effects of FK866 against traumatic brain injury: Involvement of p38/ERK pathway.Annals of clinical and translational neurology · 2020Article
- Selenium Enhances the Apoptotic Efficacy of Docetaxel Through Activation of TRPM2 Channel in DBTRG Glioblastoma Cells.Neurotoxicity research · 2019Article
- FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.Oncology letters · 2018Article
- Neuroprotective Effect of Artesunate in Experimental Model of Traumatic Brain Injury.Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging data implicate nicotinamide phosphoribosyl transferase (NAMPT) in the pathogenesis of cancer and inflammation. NAMPT inhibitors have proven beneficial in inflammatory animal models of arthritis and endotoxic shock as well as in autoimmune encephalitis. Given the role of inflammatory responses in spinal cord injury (SCI), the effect of NAMPT inhibitors was examined in this setting.
methodsWe investigated the effects of the NAMPT inhibitor FK866 in an experimental compression model of SCI.
resultsTwenty-four hr following induction of SCI, a significant functional deficit accompanied widespread edema, demyelination, neuron loss and a substantial increase in TNF-α, IL-1β, PAR, NAMPT, Bax, MPO activity, NF-κB activation, astrogliosis and microglial activation was observed. Meanwhile, the expression of neurotrophins BDNF, GDNF, NT3 and anti-apoptotic Bcl-2 decreased significantly. Treatment with FK866 (10 mg/kg), the best known and characterized NAMPT inhibitor, at 1 h and 6 h after SCI rescued motor function, preserved perilesional gray and white matter, restored anti-apoptotic and neurotrophic factors, prevented the activation of neutrophils, microglia and astrocytes and inhibited the elevation of NAMPT, PAR, TNF-α, IL-1β, Bax expression and NF-κB activity.We show for the first time that FK866, a specific inhibitor of NAMPT, administered after SCI, is capable of reducing the secondary inflammatory injury and partly reduce permanent damage. We also show that NAMPT protein levels are increased upon SCI in the perilesional area which can be corrected by administration of FK866.
conclusionsOur findings suggest that the inflammatory component associated to SCI is the primary target of these inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.